RE:Vision Invites you to a Virtual Continuing Education Event

Join us for a Special Private Lecture by Roy Rubinfeld, MS, MD: Inventor of the less-invasive epithelium-on crosslinking (CXL) system, shown in large research studies to be highly effective in stopping keratoconus vision loss and avoiding the risks and slow recovery of surgical removal of the corneal epithelium.

Wait, What?
When Did these Facts Change?

And How to Avoid Getting Sued by Knowing Them

Roy S. Rubinfeld, MA, MD
Re:Vision, Fairfax, VA and Rockville, MD

Georgetown University Medical Center, Washington Hospital Center, Washington, DC

If you think you’re up to date, take our 3-minute quiz!

About Dr. Rubinfeld
Re:Vision offers expertise where it matters most — your vision. The advanced ophthalmology practice of Dr. Roy Rubinfeld specializes in less invasive keratoconus treatments and laser vision correction. Dr. Rubinfeld founded Re:Vision in 2013, but he’s been providing expert treatment and advancing research for more than 25 years.

Don’t Take Our Word For It, Here’s The Research
CXLUSA is the world’s largest research study group that has researched and developed minimally-invasive treatment of keratoconus and post-LASIK ectasia using epithelium-on corneal crosslinking (CXL).

Wait, What? WHEN DID THESE "FACTS" CHANGE?

<span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span>